Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 3/20 | 0.31 |
| ▸ | CASP1 | P29466 | 3/20 | 0.31 |
| ▸ | CASP3 | P42574 | 3/20 | 0.31 |
| ▸ | CASP7 | P55210 | 3/20 | 0.31 |
| ▸ | CASP6 | P55212 | 3/20 | 0.31 |
| ▸ | CASP8 | Q14790 | 3/20 | 0.31 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832617 | 0.96 | NR1H4 (0.39) | NR1H4 | |
| SCHEMBL3836150 | 0.95 | NR1H4 (0.34) | NR1H4HTRA1CTSD | |
| SCHEMBL4617149 | 0.94 | NR1H4 (0.35) | NR1H4CTSD | |
| SCHEMBL6157024 | 0.92 | NR1H4 (0.34) | NR1H4CTSD | |
| SCHEMBL5821003 | 0.92 | NR1H4 (0.39) | NR1H4CTSD | |
| SCHEMBL14895557 | 0.92 | NR1H4 (0.42) | NR1H4CTSD | |
| SCHEMBL4630507 | 0.92 | NR1H4 (0.39) | NR1H4CTSD | |
| SCHEMBL5709100 | 0.90 | NR1H4 (0.40) | NR1H4 | |
| SCHEMBL14895745 | 0.90 | NR1H4 (0.33) | NR1H4CTSD | |
| SCHEMBL3836011 | 0.89 | NR1H4 (0.34) | NR1H4CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517883-B8 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-05-21 | — | — | EP | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1699758-A1 | DIPHENYLAZETIDINONE DERIVATES PROCESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1572626-A1 | THERAPEUTIC AGENTS | Astrazeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005061451-A1 | DIPHENYLAZETIDINONE DERIVATES PROCESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| EP-1521742-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| EP-1517883-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| EP-1458673-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) | Astrazeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004056748-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004005247-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004000790-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003051821-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |